Newsroom

Scientists have developed a single point-of-care assay that identifies malaria, typhoid—or both simultaneously—in just 15 minutes.

Currently, there is little research focused on understanding mechanisms and drug discovery of lymphatic vascular diseases. However, conditions such as lymphedema, a buildup of fluid in the body when the lymph system is damaged, impact more than 200,000 people every year in the United States alone.

NIBIB grantee Wilbur Lam was quoted in this Washington Post article about the ‘test to treat’ COVID-19 plan. Lam leads the Atlanta Center for Microsystems Engineered POC Tech at Emory University, which has been evaluating COVID-19 tests for RADx®.

Bioengineers at the National Institute of Biomedical Imaging and Bioengineering (NIBIB) are asking big questions—and striking up trans-NIH collaborations to answer them. And by joining forces with researchers across NIH’s intramural research program (IRP), they’re moving discovery into entirely new places. Read more at the NIH Catalyst.

Monitoring vitals and diagnosing ailments can be clunky, painful and inconvenient. But researchers like NIBIB-funded Huanyu “Larry” Cheng at Penn State are working to improve health monitoring by creating wearable sensors that collect data for clinicians while limiting discomfort for patients.

In a new study published in Science Translational Medicine, researchers demonstrated that human kidney organoids are useful models to identify the point of permanent and reversible kidney cell damage and they also discovered a drug candidate that could potentially prevent chronic disease before reaching that point. Read more at STAT.

NIBIB-funded researchers are developing a robotic pill that, after swallowing, can deliver biologic drugs into the stomach, which could provide an alternative method for self-injection for a wide range of therapies.

Ultrasound scans, best known for monitoring pregnancies or imaging organs, can also be used to stimulate cells and direct cell function. A team of Penn State researchers has developed an easier, more effective way to harness the technology for biomedical applications.

RADx Tech program has issued contracts to help meet the ongoing needs and challenges of COVID-19 diagnostic testing.